SS Innovations International Inc. (NASDAQ: SSII) is steadily building a position in telerobotic surgery, a field that is moving from isolated demonstrations toward broader clinical and regulatory development. The company’s founder and CEO, cardiac surgeon Dr. Sudhir Srivastava, recently told MedTech Dive that robotic surgery is inherently a form of teleoperation, and that the key technical challenge is determining how much distance can be introduced without compromising responsiveness. That question is central as remote procedures gain traction worldwide.
As of September 28, 2026, SS Innovations reported 195 robotic telesurgeries using its SSi Mantra system, including cardiac procedures and long-distance operations. The installed base of SSi Mantra systems reached 244, up 45% from the end of 2025, while cumulative procedures climbed to 14,503. The system has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad. These milestones underscore the company’s growing international presence and clinical experience.
The broader interest in telerobotic surgery is putting SS Innovations International (NASDAQ: SSII) and Dr. Srivastava in an increasingly relevant part of the surgical robotics market. A recent MedTech Dive report, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology’s development and the regulatory and infrastructure questions surrounding remote surgery. The article highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL). This recognition comes as the SSi Mantra system accumulates telesurgery experience, with the company pursuing U.S. FDA clearance and European Union CE marking to expand into additional international markets.
For investors, the implications are significant. Telerobotic surgery could address surgeon shortages and improve access to specialized care in remote or underserved regions. SS Innovations’ progress in accumulating clinical data and regulatory submissions may position it to compete in a market currently dominated by larger players. The company’s newsroom, available at https://ibn.fm/SSII, provides ongoing updates on these developments.
MissionIR, a communications platform that assists IR firms with syndicated content, distributes news about SS Innovations. It operates as part of the Dynamic Brand Portfolio at IBN, which offers wire solutions through InvestorWire and editorial syndication to 5,000+ outlets. These channels help amplify news for companies like SS Innovations, though the core value lies in the clinical and regulatory strides the company is making. As telesurgery gains ground, SS Innovations’ ability to secure approvals and demonstrate reliable outcomes will determine its long-term impact on the market.
